Biomea Fusion, Inc. (Nasdaq: BMEA) said it will release results from its Phase I GLP-131 clinical study evaluating BMF-650, an investigational oral small-molecule GLP-1 receptor agonist, on October 13, 2026.

The San Carlos, California-based clinical-stage biopharmaceutical company said its management will host a conference call and webcast at 4:30 p.m. ET to discuss the findings.

BMF-650 is one of two oral small-molecule therapies Biomea Fusion is developing, alongside icovamenib, targeting diabetes and obesity.